Connor, Clark & Lunn Investment Management Ltd. Harrow Health, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Harrow Health, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 130,424 shares of HROW stock, worth $5.09 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
130,424
Holding current value
$5.09 Million
% of portfolio
0.03%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$20.85 - $46.47 $2.72 Million - $6.06 Million
130,424 New
130,424 $5.86 Million
Q3 2023

Nov 13, 2023
BUY
$14.03 - $22.08 $313,879 - $493,973
22,372 Added 66.84%
55,842 $802,000
Q2 2023

Aug 10, 2023
SELL
$17.37 - $28.08 $43,442 - $70,228
-2,501 Reduced 6.95%
33,470 $637,000
Q1 2023

May 09, 2023
BUY
$13.84 - $21.46 $497,838 - $771,937
35,971 New
35,971 $761,000
Q3 2020

Nov 12, 2020
SELL
$4.71 - $7.36 $86,904 - $135,799
-18,451 Closed
0 $0
Q2 2020

Aug 13, 2020
SELL
$3.61 - $6.47 $42,428 - $76,041
-11,753 Reduced 38.91%
18,451 $96,000
Q1 2020

May 13, 2020
BUY
$3.5 - $7.31 $6,212 - $12,975
1,775 Added 6.24%
30,204 $115,000
Q4 2019

Feb 12, 2020
BUY
$4.6 - $7.88 $46,000 - $78,800
10,000 Added 54.26%
28,429 $221,000
Q3 2019

Nov 13, 2019
BUY
$4.89 - $8.0 $12,733 - $20,832
2,604 Added 16.45%
18,429 $104,000
Q2 2019

Aug 07, 2019
BUY
$4.2 - $8.7 $66,465 - $137,677
15,825 New
15,825 $138,000

Others Institutions Holding HROW

# of Institutions
176
Shares Held
21.4M
Call Options Held
845K
Put Options Held
717K
View Full List

About HARROW HEALTH, INC.

HROW Quotes by TradingView
  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $1.06B
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email